YUNGJIN PHARM. CO., LTD
Financials
Valuation Metrics
YUNGJIN PHARM. CO., LTD's Market Cap is ₩2176B. At end of 2025 it was ₩3658B. Ranked #770 of 2,436 in KR market (top 32%), #429 of 787 on KOSPI (top 55%), #86 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 37%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 217.64B KRW | KR#770/2,436 Sec#86/234 |
| Revenue | 253.94B KRW | KR#890/2,436 Sec#44/234 |
| Net Income | -3.49B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 233.82B KRW | KR#1,173/2,436 Sec#84/234 |
| Net Assets | 88.81B KRW | KR#1,471/2,436 Sec#122/234 |
| Employees | 628 | KR#399/2,436 Sec#34/234 |
| Value | ||
| P/B | 2.45x | KR#2,026/2,436 Sec#155/234 |
| P/S | 0.86x | KR#1,281/2,436 Sec#69/234 |
| FCF Yield | 0.25% | KR#1,200/2,436 Sec#90/234 |
| Profitability | ||
| ROE | -3.93% | KR#1,710/2,436 Sec#124/234 |
| ROA | -1.49% | KR#1,651/2,436 Sec#117/234 |
| Op. Margin | -0.38% | KR#1,622/2,436 Sec#116/234 |
| Revenue Growth | -0.49% | KR#1,473/2,436 Sec#141/234 |
| Earnings Growth | -333.74% | KR#1,582/2,436 Sec#104/234 |
| Financial Health | ||
| Debt Ratio | 263.28% | KR#2,039/2,436 Sec#214/234 |
| Total Debt | 83.87B KRW | KR#785/2,436 Sec#51/234 |
| FCF | 545.9M KRW | KR#1,179/2,436 Sec#90/234 |
| Cash | 6.27B KRW | KR#1,906/2,436 Sec#168/234 |
| Current Ratio | 1.66x | KR#1,183/2,436 Sec#129/234 |
| Performance | ||
| 1Y Return | -44.00% | KR#1,934/2,436 Sec#171/234 |
| 1M Return | -0.83% | KR#980/2,436 Sec#92/234 |
| From 52W High | -48.71% | KR#1,131/2,436 Sec#97/234 |
| 1Y MDD | -53.18% | KR#1,066/2,436 Sec#88/234 |
| Trading | ||
| Volume | 227,366 shares | KR#520/2,436 Sec#53/234 |
| Foreign Own. | 2.87% | KR#1,012/2,436 Sec#100/234 |
| Per Share | ||
| EPS | -19 KRW | KR—/2,436 Sec—/234 |
| BPS | 486 KRW | KR#2,392/2,436 Sec#228/234 |
Company Info
Youngjin Pharm was established in 1962 for pharmaceutical manufacturing and sales, and listed in 1973, playing a pivotal role as an affiliate of the KT&G Group. The company sells specialty pharmaceuticals such as 'Harmonylan' and 'Fivero', exports antibiotics and raw materials, and aims to strengthen its competitiveness in domestic and international markets. Youngjin Pharm secures growth engines through R&D investment and leads fair and transparent ethical management via a self-compliance program and ISO37001 certification. Its headquarters are in Songpa-gu, Seoul Metropolitan City.